Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End-Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects
Dymond, Angela W., Martin, Paul, So, Karen, Huang, Yifan, Severin, Paul, Holmes, Victoria, Mariani, Gabriella, Marbury, ThomasVolume:
57
Language:
english
Journal:
The Journal of Clinical Pharmacology
DOI:
10.1002/jcph.848
Date:
May, 2017
File:
PDF, 264 KB
english, 2017